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Commercially available clinical decision support systems (CDSSs) for skin cancer have been designed for the detection ofmelanoma
only. Correct use of the systems requires expert knowledge, hampering their utility for nonexperts. Furthermore, there are no
systems to detect other common skin cancer types, that is, nonmelanoma skin cancer (NMSC). As early diagnosis of skin cancer is
essential, there is a need for a CDSS that is applicable to all types of skin lesions and is suitable for nonexperts. Nevus Doctor (ND) is
a CDSS being developed by the authors.We here investigate ND’s ability to detect bothmelanoma andNMSC and the opportunities
for improvement. An independent test set of dermoscopic images of 870 skin lesions, including 44 melanomas and 101 NMSCs,
were analysed by ND. Its sensitivity to melanoma and NMSC was compared to that of Mole Expert (ME), a commercially available
CDSS, using the same set of lesions. ND and ME had similar sensitivity to melanoma. For ND at 95% melanoma sensitivity, the
NMSC sensitivity was 100%, and the specificity was 12%. The melanomas misclassified by ND at 95% sensitivity were correctly
classified by ME, and vice versa. ND is able to detect NMSC without sacrificing melanoma sensitivity.
1. Introduction
Melanoma is the deadliest of all skin cancers. When it is
detected early, the treatment is excision of the tumour, and
the survival rate is high. Recent developments in melanoma
treatment are promising [1, 2], but the survival rate for
patients with metastasised melanoma is still poor [3, 4].
Early diagnosis is crucial, but challenging, since early stage
melanomas resemble benign skin lesions. Other types of
skin cancer, like basal cell carcinoma (BCC) and squamous
cell carcinoma (SCC), have high incidence rates but low
mortality rates [4]. Early detection is beneficiary for the
patient to get early treatment and avoid further damaging of
the surrounding skin.
Thedermoscope (dermatoscope, epiluminescencemicro-
scope) reveals structures not visible to the naked eye and
has proven to raise diagnostic accuracy of melanoma when
used by properly trained personnel [5]. Dermoscopy has
not reached widespread use among general practitioners
(GPs), except in Australia [6]. In view of increasedmelanoma
incidence rates, national screening programmes, and growing
awareness of skin cancer in the public, there seems to be a
need for clinical decision support systems (CDSSs) for GPs
not familiar with dermoscopy.
For the past few decades, many CDSSs (also referred
to as computer-aided diagnostic (CAD) systems) have been
developed for melanoma detection. For a description of the
major steps and an overview of different technologies, see,
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for example, [7]. The review paper of Rosado et al. [8] from
2003 concluded that the diagnostic accuracy of the CDSSs
was statistically not superior to that of human diagnosis.
Vestergaard and Menzies [9] reported the same in 2008, and
Korotkov and Garcia [10] made a similar conclusion in 2012.
Simultaneously high sensitivity and specificity scores have
been reported [11], but the scores droppedwhen the same sys-
tems were tested in clinical-like settings with an independent
test set of consecutively collected images. Dreiseitl et al. [12]
concluded that the performance of their system in a clinical-
like setting was significantly lower than the result obtained
during training. Elbaum et al. [13] reported 100% sensitivity
and 85% specificity on the training set, with a dramatic drop
in specificity to 9% on an independent test set [14]. Also,
Bauer et al. reported better results for the training set [15] than
those achieved with an independent test set [16]. The good
results of Hoffmann et al. [17] were reproduced in a small
study with only 6 melanomas [18] but declined in another
small study [19]. In two other small studies with independent
test sets [20, 21], the performance reported by Blum et al. [22]
declined.There are several possible explanations for the drop
in performance. In studies where cross-validation has been
used to validate the performance, the whole data set is used
for feature selection or model selection, which gives overly
optimistic results [23, 24]. Also, several studies exclude non-
melanocytic lesions post hoc based on the pathology reports,
which introduces bias.
Differentiating between melanocytic and nonmelano-
cytic lesions can be challenging even for experienced dermo-
scopy users [25], and it is recommended that a CDSS for
melanoma detection can handle nonmelanocytic lesions as
well [8, 11, 26]. A lesion is classified as suspicious if it resem-
bles amelanoma, but lesions that resembleNMSC should also
be classified as suspicious, especially when used by GPs [27],
and not be classified together with nonsuspicious lesions.
In this report we present the performance of a CDSS for
melanoma detection, Nevus Doctor (ND), when applied to
bothmelanocytic and nonmelanocytic lesions. To our knowl-
edge, this has not been previously presented for image-based
CDSSs. Shimizu et al. [28] included BCC but excluded other
NMSCs. Several studies have included nonmelanocytic
lesions, but without reporting sensitivity to NMSC [14–17,
29–31] or with less than three NMSCs [20, 32]. Recently,
non-image-based technologies for melanoma detection have
includedNMSC sensitivity in their reported findings [33, 34].
There is no apparent ranking of the CDSSs for melanoma
detection. In practice, CDSSs can only be compared if tested
on the same set of lesions, as done by Perrinaud et al. [32].
We therefore compare the performance of ND to that of a
commercially available system, Mole Expert (ME), on the
same set of lesions. This methodology potentially identifies
the diagnostic difficulty of the data set, supplementing the
information on the proportion of melanomas in situ, Breslow
depth, clinical diagnoses, and so forth. It also allows for
indirect comparison of CDSSs if, in the future, some study
chose to compare another system to ME.
2. Materials and Methods
2.1. Data. From March to December 2013, patients were
recruited at a private dermatology practice in Pulheim,
Germany. Adult patients scheduled for excision of a pig-
mented skin lesion were eligible for inclusion. Further-
more, patients who were having nonpigmented skin lesions
excised were eligible for inclusion if melanoma, BCC, or
SCC was a potential differential diagnosis. Patients attending
the German skin cancer screening programme [35] were
also eligible for inclusion if they had skin lesions selected
for excision. Informed written consent was obtained from
all patients prior to inclusion. Skin lesions were excised
because of concern about malignancy or when requested by
the patient for other reasons. All skin lesions were photo-
graphed prior to excision with a digital camera (Canon G10,
Canon Inc., Tokyo, Japan) with an attached dermoscope
(DermLite FOTO, 3Gen LLC, California, USA) and with a
videodermoscope (DermoGenius ultra, DermoScan GmbH,
Regensburg, Germany). All excised lesions were examined by
a dermatopathologist. In the case of a malignant diagnosis, a
second dermatopathologist examined the excised lesion and
a consensus diagnosis was set.
2.2. Automatic Image Analysis. ND takes a dermoscopic
image from the Canon/DermLite device as input and clas-
sifies the lesion. ND is still in an experimental phase. In a
previous study, ND performed as well as three independent
dermatologists in terms of melanoma sensitivity and speci-
ficity [36]. In another study, ND performed as well as an
independent dermatologist on an independent test set con-
sisting of 21melanomas and 188 benign lesions [37].The data
set in this study partly overlaps with the test set in Møllersen
et al. [37], but not with the training set. ND has not been
retrained, so the present data set is independent. ND outputs
a probability of malignancy for each lesion image, and the
sensitivity can be tuned with a parameter 𝛼 (see [36–38] for
details).
ME (MoleExpert micro Version 3.3.30.156) takes a der-
moscopic image from the DermoGenius device as input. The
output is a number between −5.00 and 5.00, where high
values indicate suspicion of melanoma, and the sensitivity
can be tuned by adjusting a threshold 𝑡. ME is intended
for use on melanocytic lesions only. ME was chosen as the
comparison system due to availability and the fact that it has
been tested and compared to other commercial systems in
clinical settings on a small scale [29, 32]. To our knowledge,
the study of Perrinaud et al. [32] is the only study that
compares several systems on the same set of lesions, and it
is therefore not possible to pick the most adequate reference
system.
2.3. Statistical Analysis. All excised lesions for which a
pathology report was available were included in the analysis.
Cases were excluded if either of the CDSSs could not give
an output or if images were missing. Presence of hairs and
bubbles, lesion size, inadequate segmentation, and so forth
were not used as exclusion criteria. The data was divided
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into four classes according to the histopathological diag-
nosis: melanoma, NMSC, benign melanocytic lesions, and
benign nonmelanocytic lesions.Themelanoma class includes
lesions where malignancy could not be ruled out by the
dermatopathologists (ICD-10 D48.5), and the NMSC class
includes precancerous lesions, as done in other studies [33,
34]. Precancerous lesions should be classified as suspicious,
since the patient should receive treatment or follow-up.
The sensitivity and specificity scores of ND and ME were
calculated by adjusting parameters 𝛼 and 𝑡 and classifying
the lesions accordingly. Sensitivity refers to the ratio of
malignant lesions classified as suspicious to the total number
of malignant lesions. Since there are two classes of malignant
lesions, the termsmelanoma sensitivity andNMSC sensitivity
are used for clarification when needed.
The clinical diagnoses are taken from the dermatologist’s
referrals to pathology. The clinical malignant class includes
lesions where malignancy is a differential diagnosis. The
clinical benign class consists of lesions that were given a
benign diagnosis by the dermatologist but were referred to
pathology, which indicates that malignancy could not be
ruled out by the dermatologist, even if this was not explicitly
stated.
3. Results and Discussion
3.1. Results. There were 516 consultations (47% women)
included in the study and a total of 877 excised lesions.
The minimum age was 18, the maximum age was 93, and
median age was 53 years. Table 1 shows the histopathological
diagnoses. The ratio of benign lesions per melanoma was
16 : 1, which is within the range for dermatologists [39, 40].
In total, 5% of the lesions were melanomas. The median
Breslow depth for the 23 invasive melanomas was 0.50mm,
and the maximum Breslow depth was 2.25mm. Table 2
shows the diagnoses and the Breslow depths according to
the 2009 American Joint Committee on Cancer (AJCC)
staging [41]. About 70% of the melanomas and about 90%
of the NMSCs were clinically diagnosed as malignant. One
lesion lacked clinical diagnosis. Of the 875 lesions with
histopathological diagnosis, four were excluded because ME
did not give an output (one naevus, one seborrheic keratosis,
one BCC, and one SCC) and one was excluded because the
Canon/DermLite image was lost (melanoma in situ), which
corresponds to less than 1% of the images. In comparison,
10% of the lesions were excluded due to lesions size or device
malfunctions in the study by Malvehy et al. [33].
Figure 1(a) shows receiver operating characteristic (ROC)
curves for ND and ME. The red and blue solid curves show
sensitivity versus specificity for the whole data set where
the malignant class includes both melanoma and NMSC,
and a clear distinction between ND and ME can be seen.
The pink and turquoise dotted curves show sensitivity versus
specificity for melanocytic lesions only, and there is no
significant difference betweenND andME. Figure 1(b) shows
NMSC sensitivity as a function of melanoma sensitivity.
The boxplots in Figure 2 illustrate each CDSS’s ability to
discriminate between the different classes of lesions. For both
Table 1: Histopathological diagnoses for the 877 skin lesions.
Histopathological diagnosis Total: 877
Benign lesions 727
Melanocytic lesions 596
Naevus 574
Naevoid lentigo 9
Blue naevus 8
Spitz naevus 4
Sutton naevus 1
Nonmelanocytic lesions 118
Seborrheic keratosis 80
Lentigo senilis 9
Neurofibroma 5
Dermatofibroma 8
Hemangioma 4
Verruca 2
Acanthoma 3
Papilloma, fibroma molle, sebaceous gland
hyperplasia, scar, eczema, folliculitis, and
diskoid lupus erythematodes
7
Collision tumours 13
Malignant and precancerous lesions 148
Melanoma 45
Invasive melanoma 25
Melanoma in situ 20
Nonmelanoma skin cancers 103
Adnexal carcinoma 1
Actinic keratosis 13
Basal cell carcinoma 71
Squamous cell carcinoma 7
Bowen’s disease 11
No histopathological diagnosis 2
Table 2: Characteristics of the 45melanomas.
Diagnosis/Breslow Number
In situ 13
Lentigo maligna 7
Cutaneous metastasis 2
≤1.00mm 19
1.01–2.00mm 3
2.01–4.00mm 1
>4.00mm 0
ND and ME, there is an overlap between melanomas in situ
and benignmelanocytic lesions, whereas invasivemelanomas
can be separated from benign melanocytic lesions. ND has
high scores for NMSC, but also for benign nonmelanocytic
lesions. ME has greater relative variety for all categories than
ND has which lead to larger overlaps and thusmore difficulty
in distinguishing the different categories.
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Figure 1: (a) Receiver operating characteristic curves for Nevus Doctor and Mole Expert. (b) Nonmelanoma skin cancer sensitivity as a
function of melanoma sensitivity.
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Figure 2: Boxplots for (a) Nevus Doctor and (b) Mole Expert.The horizontal lines inside the boxes are the medians; the boxes are defined by
the 25th and 75th percentiles. The whiskers are situated at two standard deviations from the mean. The crosses indicate outlier observations.
For ND at 95%melanoma sensitivity, the overall sensitiv-
ity was 99%, the specificity was 12%, the positive predictive
value (PPV) was 18%, and the negative predictive value
(NPV) was 98%, where sensitivity, specificity, PPV, and NPV
are defined in terms of malignant (melanoma and NMSC)
and benign histopathological diagnosis. Figure 3 shows the
two melanomas that were misclassified at 95% melanoma
sensitivity for each CDSS. They were all in situ and were all
clinically diagnosed as benign.
3.2. Discussion. The ROC curves for ND and ME in
Figure 1(a) show that ND performed similar to ME when
nonmelanocytic lesions were excluded, and by that we
have shown that ND performed similarly to ME under
the circumstances for which ME is intended. When non-
melanocytic lesions were included, ND performed better
than ME. Figure 1(b) shows that ND’s NMSC sensitivity
reached 100% at melanoma sensitivity of 86%, which means
that, at reasonably high melanoma sensitivity, all NMSCs
were classified as suspicious.
The majority of the benign lesions were excised due to
suspicion of malignancy, and about 30% of the melanomas
had a benign clinical diagnosis, so the overlap between
benignmelanocytic lesions andmelanomas in situ, as seen in
Figure 2, was expected. NDmisclassifies seborrheic keratoses
as suspicious, similar to other CDSSs [20, 31–33]. GPs excise
BioMed Research International 5
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Figure 3: (a)–(d) Lesions photographed with Canon/DermLite. (e)–(h) Lesions photographed with DermoGenius. ((a)-(b) and (e)-(f)) The
two melanomas misclassified by ND at 95% melanoma sensitivity. ((c)-(d) and (g)-(h)) The two melanomas misclassified by ME at 95%
melanoma sensitivity.
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Figure 4: Receiver operating characteristic curves forNevusDoctor
and Mole Expert. Upper right part of Figure 1(a).
more seborrheic keratoses per melanoma than dermatolo-
gists do [39, 40, 42], so there is a potential for saving pathol-
ogy resources if a CDSS can classify them correctly. Devel-
opment of image analysis features to discriminate seborrheic
keratosis from melanoma has just begun [28].
Only the segment of the ROC curve with high sensitivity
to melanoma, as shown in Figure 4, is clinically relevant,
and therefore the area under the curve (AUC) is not an
adequate summary of a CDSS’s performance. The area under
the clinically relevant segment of the ROC curve would be a
more adequate summary statistic; however, then the clinically
relevant segment must first be defined.
Inadequate segmentation was not used as exclusion cri-
terion, although it seems unlikely that a user would trust
the outcome if the segmentation fails. But since there is no
ground truth for segmentation, it is less suited as exclusion
criterion. The decision to carry out excision was based on
only one dermatologist’s opinion, which is a drawback since
interobserver agreement is only moderate for dermatologists
[25]. Short-term follow-up of the patient or consensus diag-
nosis based on dermoscopic and clinical images can be used
as the gold standard for nonexcised lesions, but it requires
large resources.The data set used in this study is independent
of all stages of ND’s development, but the lesions in this set
are possibly more similar to the lesions ND has been trained
on than to the lesions ME has been trained on, and this is
potentially an advantage for ND.
The present data set consisted of 44% melanomas in
situ and median Breslow depth of 0.50mm, which indicate
high diagnostic difficulty. A proportion of 31% melanomas
in situ was reported on a similar population in Germany
[43]. The data set consists of 44 melanomas, which is more
than most reported studies of CDSSs with independent test
sets, with some exceptions [14, 33]. With 44 melanomas,
95% melanoma sensitivity means that only two melanomas
are misclassified, and the results are therefore very sensitive
to small changes in the data set. Confidence intervals for
highly data sensitive results can give a false impression of
generalisability and are therefore not reported.
ND andMEmisclassified different melanomas, as shown
in Figure 3, which is not unexpected since the two CDSSs
have been developed independently of each other. It has been
reported that the sensitivity and specificity for dermatologists
improve whenmajority vote or consensus is used to diagnose
skin lesions [5, 25]. We have investigated whether a combi-
nation of ND and ME will increase the sensitivity without
decreasing the specificity. Figure 5 shows the ROC curve for
a classifier which classifies a lesion as suspicious if either
ND or ME classifies it as suspicious. For melanocytic lesions
only, this classifier outperformedND andME for sensitivities
6 BioMed Research International
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Figure 5: Receiver operating characteristic curves for Nevus Doctor, Mole Expert, and the combination classifier. Melanocytic lesions only.
(a) (b)
Figure 6: Lesion (a) was clinically diagnosed as naevus, whereas lesion (b) was clinically diagnosed as melanoma.
above 90%. For melanoma and NMSC, the performance was
about the same as for ND (not shown). An explanation of
the results can be that the lesions were photographed with
different cameras and dermoscopes, but it can also be because
of the different feature algorithms or different statistical
classifiers.
A CDSS is not needed for skin lesions that obviously are
melanomas, and it can therefore be argued that these lesions
should be excluded [14]. To evaluate ND’s performance
under these conditions, all melanomas that were clinically
diagnosed asmelanomawith no benign differential diagnosis
were excluded. There were then 22 melanomas left. Tun-
ing the parameters to 95% melanoma sensitivity (21 of 22
melanomas detected) gave a specificity of 6% for ND and 13%
for ME, similar to the 9% specificity reported by Monheit et
al. [14]. One should, however, be very cautious when drawing
conclusions. To demonstrate the dependence on the data set,
one of the melanomas clinically diagnosed as benign was
replaced by a melanoma clinically diagnosed as malignant,
shown in Figure 6. The specificity then increased to 12% for
ND and decreased to 7% for ME, which is outside the range
of the respective confidence intervals.
Compared to other studies with independent test sets
and a minimum of 10 melanomas [12, 14, 16, 33, 34], the
sensitivity and specificity scores of ND and ME are not
superior. Inclusion of nonexcised lesions [12, 34] can have a
positive effect on the observed specificity, since these lesions
do not resemble malignant lesions. A higher proportion of
melanomas in situ decreases the observed performance of
the system as shown in Figure 2 and also illustrated by
Malvehy et al. [33]. Whether the superior performance of
Piccolo et al. [16] is due to fewmelanomas in situ is unknown,
as this was not reported. The two studies with more than
100 melanomas in an independent test set reported similar
sensitivities (98% and 97%) but different specificities (9% and
34%), but it is not possible to conclude that one system is
better than the other, since the exclusion criteria for the two
studies are very different. A publicly available data set has
been called for [8], but the wide variety of technologies is a
challenge.
4. Conclusions
We have shown that ND was able to detect NMSC without
sacrificing melanoma sensitivity but misclassified benign
nonmelanocytic lesions. Although there are promising results
for other technologies, dermoscopy is still the only widely
used tool for skin lesion diagnosis. Nonmelanocytic lesions
are an important aspect in melanoma detection, and more
research is needed, especially on features for differentiating
between melanomas and seborrheic keratoses.
Different inclusion and exclusion criteria,moderate-sized
data sets, and variety in the diagnostic difficulty make the
reported sensitivity and specificity scores inadequate for
comparing different CDSSs.The demonstration of the results’
dependence on the data set emphasises the need for direct
comparison on the same set of lesions. Which system is the
BioMed Research International 7
most adequate for comparison will remain unknown until
more studies are reported.
According to a study by Dreiseitl and Binder [44], physi-
cians are willing to follow the recommendation of a CDSS,
especially if they are not confident in their own diagnosis, and
Fru¨hauf et al. [20] reported that patients accept the use of a
CDSS. Hence, there is a potential for CDSSs in melanoma
detection if the systems can give reliable recommendations
for all kinds of lesions.
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